Hero Image

5 GI-Recommended Medications for Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that can be effectively managed with the right treatment plan.

In this guide, we break down five medications/treatment classes gastroenterologists frequently recommend, explain what sets each apart, and share practical steps for choosing a therapy and finding the right specialist.

5 gastroenterologist‑recommended, evidence‑backed treatments

Recommendations below align with major guidelines from the American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and the European Crohn’s and Colitis Organisation (ECCO). These sources summarize high‑quality trials and real‑world outcomes.

Your personal treatment plan depends on disease severity, prior therapies, comorbidities, and preferences (pill vs infusion/injection), so discuss options with your gastroenterologist.

1) Mesalamine (5‑ASA) for mild to moderate UC

Why it stands out: Mesalamine acts directly on the colon lining to reduce inflammation and is a first‑line option for many with mild to moderate UC. It’s available as oral tablets/capsules and rectal formulations (suppositories/enemas) that target disease in the rectum and left colon. It has a favorable safety profile compared with systemic immunosuppressants.

Evidence highlight: Multiple reviews support 5‑ASA for inducing and maintaining remission, particularly in mild disease. See Cochrane evidence on maintenance of remission with 5‑ASA here, and guideline endorsements from ACG and AGA.

Best for: Mild to moderate UC, especially left‑sided/proctitis when combined with rectal mesalamine. Many patients stay on mesalamine long‑term to help maintain remission under clinician guidance.

2) Corticosteroids for short‑term flare control

Why it stands out: Steroids (e.g., prednisone; budesonide MMX) can quell moderate to severe flares quickly. Budesonide MMX is designed to act locally in the colon with lower systemic exposure than traditional steroids.

Evidence highlight: Budesonide MMX 9 mg has demonstrated efficacy in inducing remission in active UC in randomized trials (CORE I/II). Guidelines stress steroids are for induction only, not maintenance, due to side effects and dependency risks (ACG; AGA).

Best for: Moderate to severe flares requiring rapid symptom control while transitioning to a maintenance therapy. Your care team will aim to taper off steroids once a maintenance agent is effective.

3) Anti‑TNF biologics (infliximab, adalimumab, golimumab)

Why it stands out: Anti‑TNF agents target tumor necrosis factor‑alpha, a key inflammatory cytokine. They’re proven to induce and maintain remission, promote mucosal healing, and reduce hospitalizations in moderate to severe UC. Biosimilar versions have expanded access in many regions.

Evidence highlight: Landmark trials include infliximab (ACT 1/2) showing induction and maintenance benefits (NEJM/ACT trials). Guidelines recommend anti‑TNFs for moderate to severe disease and for patients with steroid‑dependence or steroid‑refractory UC (AGA; ACG).

Best for: Moderate to severe UC; can be used first‑line among advanced therapies, especially when rapid control and hospitalization avoidance are priorities. Combination with a thiopurine can reduce immunogenicity in select cases—your GI will weigh risks/benefits.

4) Vedolizumab (anti‑integrin, gut‑selective)

Why it stands out: Vedolizumab blocks gut‑homing lymphocytes, concentrating its effect in the intestine with less systemic immunosuppression. Many clinicians favor it for patients prioritizing a favorable long‑term safety profile.

Evidence highlight: The GEMINI 1 trial demonstrated vedolizumab’s efficacy for induction and maintenance in UC (GEMINI 1). AGA and ECCO guidelines endorse vedolizumab as a first‑line advanced therapy option in moderate to severe UC (AGA; ECCO).

Best for: Moderate to severe UC, particularly for patients with infection or malignancy risk concerns where gut‑selective activity is desirable.

5) JAK inhibitors (tofacitinib, upadacitinib)

Why it stands out: Oral small‑molecule pills that can work quickly—even within days for some patients. They target intracellular signaling pathways driving inflammation and avoid infusion/clinic visits.

Evidence highlight: Tofacitinib showed efficacy in the OCTAVE induction/maintenance trials (OCTAVE), while upadacitinib demonstrated strong induction and maintenance results in phase 3 UC studies (U‑ACHIEVE/U‑ACCOMPLISH). Guidelines include JAK inhibitors among recommended advanced therapies for moderate to severe UC (AGA; ECCO).

Best for: Moderate to severe UC, especially when rapid symptom control is needed or prior biologics have failed. Important safety notes: JAK inhibitors carry boxed warnings for serious infections, blood clots, major cardiovascular events, and certain cancers. Your clinician will screen for risks and monitor appropriately.

How to choose the right medication for you

There’s no one‑size‑fits‑all UC plan. Most experts now use a treat‑to‑target approach—setting clear goals (clinical remission, mucosal healing) and adjusting therapy until targets are met (STRIDE‑II consensus).

  • Disease severity and extent: Mild proctitis may respond to rectal mesalamine alone; extensive or severe disease often needs advanced therapy.
  • Speed of action needed: Severe flares or hospitalization may call for fast‑acting agents (steroids initially, then anti‑TNF or JAK inhibitor).
  • Safety profile and comorbidities: Vedolizumab or ustekinumab/IL‑23 inhibitors may be favored in patients with infection or malignancy risks; JAK inhibitors require careful cardiovascular/thrombotic risk assessment.
  • Prior treatment history: Response or loss of response to a class can guide the next choice.
  • Convenience and lifestyle: Oral therapy vs injections/infusions; travel distance to an infusion center.
  • Pregnancy and family planning: Some agents have more pregnancy data than others—discuss timing with your GI and obstetric team.
  • Cost and coverage: Work with your clinic and insurer on prior authorization, copay support, and biosimilars to reduce out‑of‑pocket costs.

Other modern options your GI may discuss include IL‑12/23 or IL‑23 inhibitors (e.g., ustekinumab, mirikizumab, risankizumab) with strong evidence for moderate to severe UC (UNIFI/ustekinumab). An S1P modulator (ozanimod) is another oral option supported by phase 3 data (True North). Your doctor will tailor choices to your profile.

When to see a doctor or gastroenterologist

  • New or worsening symptoms such as blood in stool, frequent diarrhea, nocturnal symptoms, urgency, or abdominal pain
  • Signs of a significant flare: fever, dehydration, rapid heartbeat, weight loss, or inability to keep up with daily activities
  • Steroid dependence (needing repeated steroid courses or inability to taper)
  • Medication side effects (new chest pain, shortness of breath, severe infections, shingles, unexplained bruising)
  • Post‑hospitalization follow‑up after severe UC

If you’re newly diagnosed or unsure where to start, the NIDDK overview of ulcerative colitis is a reliable, patient‑friendly primer to prepare for your appointment.

How to find the right gastroenterologist for UC

  • Look for IBD experience: Seek a board‑certified gastroenterologist with a focus on inflammatory bowel disease; large centers often have dedicated IBD clinics.
  • Use trusted directories: Try the AGA’s patient directory (Find a Gastroenterologist) or check local academic medical centers for IBD programs.
  • Ask about access: Availability for urgent visits during flares, infusion services, nurse navigators, and insurance support can make day‑to‑day care smoother.
  • Discuss monitoring plans: How often will labs, fecal calprotectin, colonoscopy/flexible sigmoidoscopy, and vaccine updates be checked?

Smart add‑ons to improve outcomes

  • Combination of oral + rectal therapy: For left‑sided disease, adding rectal mesalamine to oral 5‑ASA can boost remission rates (endorsed in ACG guidelines).
  • Vaccinations and infection prevention: Before and during immunosuppression, ensure vaccines are up to date (e.g., shingles, flu, pneumococcal). See CDC guidance on care in altered immunocompetence here and review specifics with your clinician.
  • Colon cancer surveillance: Long‑standing extensive UC increases colorectal cancer risk; regular surveillance colonoscopy is recommended—timing depends on duration, extent, and risk factors (overview from the Crohn’s & Colitis Foundation here).
  • Lifestyle and nutrition: During flares, gentle, lower‑residue choices may ease symptoms; in remission, a balanced, fiber‑forward diet as tolerated supports overall health. Consider a dietitian familiar with IBD.
  • Mental health and support: Anxiety and stress can worsen symptom perception; counseling and peer support groups can help adherence and quality of life.

Key takeaways

  • For mild to moderate UC, mesalamine (5‑ASA) is a mainstay; steroids are for short‑term flare control only.
  • For moderate to severe UC, advanced therapies—including anti‑TNFs, vedolizumab, and JAK inhibitors—are guideline‑endorsed and effective.
  • Choosing a therapy is personal: align on targets, safety, speed, convenience, and cost with your gastroenterologist.
  • Know when to seek care, and partner with an IBD‑experienced GI for monitoring, vaccination, and cancer prevention.

This article is for general education and not a substitute for personalized medical advice. Always discuss diagnosis and treatment decisions with your gastroenterologist.